Skip to content

You can have confidence in your biosimilar medicines

Learn more
Switching to biosimilars is safe and effective for patients
Learn more
Previous
Next

Who we are

Biosimilars Canada is a national association representing the biosimilar medicines industry in Canada. We provide leadership in educating Canadian stakeholders about the safety and efficacy of biosimilar medicines, and advocate for policies that support their timely approval, reimbursement, market acceptance and expanded use.

About Biosimilars

As patents for original brand biologic medicines expire other manufacturers can produce new versions called biosimilars. Health Canada authorizes biosimilars for sale using the same rigorous regulatory standards as for all other biologic drugs, and there are no clinically meaningful differences in efficacy and safety between a biosimilar and the original brand biologic medicine.

Resources

Learn more about biosimilars and their benefits for patients and healthcare systems.

Latest news

New Canadian biosimilars resource

Health Canada has published a Handbook for health care professionals on biosimilar biologic drugs. 

Read more

Ontario achieves significant savings with oncology biosimilars

The use of oncology biosimilars has led to substantial annual savings in Ontario. In fiscal years 2020/21, 2021/22 and 2022/23, Ontario Health saved an estimated $53 million, $44 million, and $53 million, respectively.

Read more

PEI Announces Transition to Cost-Saving Biosimilar Medicines

Toronto – October 12, 2023 – Biosimilars Canada, a national association representing Canada’s biosimilar medicines industry, welcomes the announcement by the Government of Prince Edward Island (PEI) that it is implementing a “switching” or transitioning policy to expand the use...
Read more